Neuraxis, INC

Overview

Compare with Vivani Medical, Inc., ADM TRONICS UNLIMITED, INC. or Hongchang International Co., Ltd, or pick any stock.

• TickerNRXS on NYSE¹
• IndustryElectromedical & Electrotherapeutic Apparatus¹
• HeadquartersCarmel, Indiana¹
• Incorporated inDE²
• Business address11611 N. Meridian St, Suite 330, Carmel, In 46032²
• Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

This lack of evidence for drugs has been supported in by the American Academy of Pediatrics and NASPGHAN.³ From its latest annual report

Corporate structure

Neuraxis, INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Neuraxis, INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

Our corporate headquarters are located in Carmel, Indiana, where we lease office space for employees. The term of this lease commenced on January 1, 2024 and is scheduled to end on May 31, 2029. Over the term of the lease, the monthly base rent is $6,721 with an annual 2.5% escalator. We received a 50% reduction in our monthly rent for the first 10 months of the lease.

We also lease office space in Batesville, Indiana, pursuant to an agreement that commenced August 1, 2025 for an inital term of three years with automatic one year renewal options subject to an annual 4% rent escalation, unless 60 day notice of vacating is given. The Company prepaid $25,200 of rent on June 13, 2025 which will be amortized over the initial lease term and thereby reduced the monthly base rent to $1,300.

Item 2 of the 10-K filed Mar 19, 2026.³

Leadership

Who has led Neuraxis, INC, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerBrian Allen Carrico Aug 8, 2023 to now⁹
• Chief financial officerTimothy Robert Henrichs Sep 10, 2025 to now¹⁰
• Chief financial officerJohn G. Seale Aug 8, 2023 to Aug 8, 2023¹¹
• Chief operating officerDaniel Jerome Clarence Aug 9, 2023 to Aug 9, 2023¹²

Timeline

1. Oct 14, 20268-K Other events²⁰
2. Aug 19, 20268-K Executive or director change; Other events²¹
3. Jul 10, 20268-K Other events²²
4. Jun 12, 20268-K Shareholder vote²³
5. Apr 22, 20268-K Other events²⁴
6. Apr 21, 20268-K Results of operations²⁵
7. Oct 24, 20258-K Other events²⁶
8. Oct 23, 20258-K Results of operations²⁷
9. Sep 2, 20258-K Entered a material agreement²⁸
10. Jul 3, 20258-K Entered a material agreement; Ended a material agreement; Executive or director change²⁹
11. Jun 4, 20258-K Shareholder vote³⁰
12. May 28, 20258-K Regulation FD disclosure³¹
13. Aug 8, 2023New chief executive Brian Allen Carrico becomes CEO⁹

Calendar

Coming up

1. Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.24) a share, on Nov 10, 2025.³²

When it reported results

1. Apr 21, 2026Reported quarterly or annual results²⁵
2. Oct 23, 2025Reported quarterly or annual results²⁷
3. Jan 8, 2025Reported quarterly or annual results³³
4. Nov 12, 2024Reported quarterly or annual results³⁴
5. Aug 9, 2024Reported quarterly or annual results³⁵
6. Apr 9, 2024Reported quarterly or annual results³⁶
7. Sep 21, 2023Reported quarterly or annual results³⁷

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

193 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 36 major events, 61 insider forms, 12 large holders, 71 other. The latest 20:

1. Oct 14, 20268-K EDGAR
2. Oct 8, 20264 EDGAR
3. Oct 8, 20264 EDGAR
4. Oct 8, 20264 EDGAR
5. Sep 29, 20263 EDGAR
6. Aug 26, 20264 EDGAR
7. Aug 26, 20264 EDGAR
8. Aug 26, 20264 EDGAR
9. Aug 19, 20268-K EDGAR
10. Aug 17, 20264 EDGAR
11. Aug 17, 20264 EDGAR
12. Aug 17, 20264 EDGAR
13. Aug 17, 20264 EDGAR
14. Aug 17, 20264 EDGAR
15. Aug 17, 20264 EDGAR
16. Aug 17, 20264 EDGAR
17. Aug 17, 20264 EDGAR
18. Aug 11, 202610-Q EDGAR
19. Aug 6, 2026424B3 EDGAR
20. Aug 3, 2026EFFECT EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

10 open-market trades by officers, directors and large owners since October 2021: 8 buys and 2 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• BIGGER CAPITAL FUND L PSCHEDULE 13G/A, 5 filings Oct 9, 2025 to Aug 3, 2026³⁸
• Brian HannaschSCHEDULE 13G/A, 5 filings Dec 26, 2023 to Jul 2, 2025³⁹
• Rosalind Advisors, Inc.SC 13D, 2 filings Dec 2, 2024⁴⁰

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 31. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Neuraxis, INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARNeuraxis, INC¹
• CIK0001933567
• Employer ID (EIN)45-5079684³
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company³
• Incorporated inDelaware³
• Fiscal year endsDecember 31¹
• Industry code (SIC)3845 Electromedical & Electrotherapeutic Apparatus¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address11611 N. Meridian St, Suite 330, Carmel, IN 46032¹
• Phone(812) 689-0791¹
• Shares outstanding12,557,765 as of Aug 6, 2026⁸
• Public float$20.4M as of Jun 30, 2025³
• AuditorRosenberg Rich Baker Berman, P.A., Somerset, New Jersey PCAOB ID 89; no auditor attestation of internal control over financial reporting³
• On EDGAR sinceSep 27, 2022¹
• Filings193 in all: 4 (45), 8-K (36), 3 (15), CORRESP (12), 10-Q (10), S-1/A (8), UPLOAD (8), SCHEDULE 13G/A (6)¹
  All 34 form types

  424B5 (4), FWP (4), 10-K (3), 424B3 (3), ARS (3), DEF 14A (3), DEFA14A (3), EFFECT (3), DRS/A (2), DRSLTR (2), NT 10-Q (2), PRE 14A (2), S-3 (2), S-3/A (2), S-8 (2), SC 13G (2), SC 13G/A (2), 4/A (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), NT 10-K (1), S-1 (1), SC 13D (1), SCHEDULE 13G (1)

• Latest filingsAnnual report (10-K) Mar 19, 2026
  Quarterly report (10-Q) Aug 11, 2026
  Proxy statement (DEF 14A) Apr 28, 2026
  Latest 8-K (8-K) Oct 14, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 19, 2026 (Section 12(b) of the Exchange Act).³

Risk factors and legal proceedings

The risks Neuraxis, INC names in Item 1A of its 10-K filed Mar 19, 2026: 53 risks under these headings, as written.³

• Risks Relating to Our Business and Our Product
• Our business and prospects depend entirely on our current products, IB-Stim and RED. Even though we have received FDA clearance for our products, it will remain subject to ongoing regulatory review. If we are unable to maintain regulatory clearance and commercialize our product or are significantly delayed or limited in our commercialization efforts, our business and prospects will be materially harmed.
• To date, we have not generated any operating profits, and due to our long-term research and development efforts, we have a history of incurring substantial operating losses.
• Our clinical studies could be delayed or otherwise adversely affected by many factors, including difficulties in enrolling patients.
• If we are unable to develop an adequate sales and marketing organization or contract with third parties to assist us, we may not be able to successfully commercialize our products for current and future indications.
• The success of our business may be dependent on the actions of our collaborative partners.
• We may not be successful in achieving market acceptance of our products by healthcare professionals, patients and/or third-party payers in the timeframes we anticipate, or at all, which could have a material adverse effect on our business, prospects, financial condition and results of operations.
• Failure to secure and maintain adequate coverage and reimbursement from third-party payers could adversely affect acceptance of our products and reduce our revenues.
• We may not be successful in maintaining reimbursement codes necessary to facilitate accurate and timely billing for our products or physician services attendant to our products.
• We may depend on single-source suppliers for some of our components. The loss of these suppliers could prevent or delay shipments of our products, delay our clinical studies or otherwise adversely affect our business.
• Quality control problems with respect to devices and components supplied by third-party suppliers could have a material adverse effect on our reputation, our clinical studies or the commercialization of our products and, as a result, a material adverse effect on our business, prospects, financial condition and results of operations.
• We currently do not own a manufacturing facility and rely on contract manufacturers for the production of our products. Any significant disruption to the contract manufacturer’s operations or facilities could have a material adverse effect on our business, financial condition and results of operations.

Legal proceedings

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of the date of issuance, other than those described below, there were no pending or threatened legal proceedings that could reasonably be expected to have a material effect on the results of the Company’s operations. There are also no proceedings in which any of the Company’s directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company’s interest.

On February 6, 2019, plaintiff Ritu Bhambhani, M.D., initiated a lawsuit against Innovative Health Solutions, Inc. and others in the United States District Court for the District of Maryland. Plaintiffs Bhambhani and Sudhir Rao subsequently amended the complaint, with the Third Amended Complaint (“Complaint”) containing the most recent set of allegations. The Complaint asserted claims under the RICO Act, as well as of fraudulent misrepresentation, intentional misrepresentation by concealment, and civil conspiracy and sought compensatory damages in excess of $5 million, pre-judgment interest, punitive damages, attorney’s fees, court costs and designation of the case as a class action. The Complaint stated that the Company, distributors of the Company’s product, and medical billing and coding consultants allegedly made misrepresentations to the plaintiffs that the Company’s NeuroStim device and related procedures could be billed to, and reimbursed by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim to have suffered damages when Medicare administrative contractors declined to pay plaintiffs for their use of the device.

The opening of Item 3, Legal Proceedings.³